Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor agonist, has been used to explore its efficacy in clinical trials for the treatment of NASH, obesity, and type 2 diabetes mellitus (T2DM)338,339. This evidence concerns the gene GLP1R and diabetes mellitus.